1. Cutting Edge: Targeting Epithelial ORMDL3 Increases, Rather than Reduces, Airway Responsiveness and Is Associated with Increased Sphingosine-1-Phosphate.
- Author
-
Miller M, Tam AB, Mueller JL, Rosenthal P, Beppu A, Gordillo R, McGeough MD, Vuong C, Doherty TA, Hoffman HM, Niwa M, and Broide DH
- Subjects
- Animals, Asthma immunology, Disease Models, Animal, Lysophospholipids immunology, Lysophospholipids metabolism, Membrane Proteins immunology, Mice, Mice, Inbred C57BL, Mice, Knockout, Polymerase Chain Reaction, Respiratory Hypersensitivity immunology, Sphingosine analogs & derivatives, Sphingosine immunology, Sphingosine metabolism, Asthma metabolism, Membrane Proteins antagonists & inhibitors, Respiratory Hypersensitivity metabolism
- Abstract
In this study, we used cre-lox techniques to generate mice selectively deficient in ORMDL3 in airway epithelium ( Ormdl3
Δ2-3/Δ2-3 /CC10 ) to simulate an inhaled therapy that effectively inhibited ORMDL3 expression in the airway. In contrast to the anticipated reduction in airway hyperresponsiveness (AHR), OVA allergen-challenged Ormdl3Δ2-3/Δ2-3 /CC10 mice had a significant increase in AHR compared with wild-type mice. Levels of airway inflammation, mucus, fibrosis, and airway smooth muscle were no different in Ormdl3Δ2-3/Δ2-3 /CC10 and wild-type mice. However, levels of sphingosine-1-phosphate (S1P) were significantly increased in Ormdl3Δ2-3/Δ2-3 /CC10 mice as well as in airway epithelial cells in which ORMDL3 was inhibited with small interfering RNA. Incubation of S1P with airway smooth muscle cells significantly increased contractility. Overall, Ormdl3Δ2-3/Δ2-3 /CC10 mice exhibit increased allergen-induced AHR independent of inflammation and associated with increased S1P generation. These studies raise concerns for inhaled therapies that selectively and effectively inhibit ORMDL3 in airway epithelium in asthma., (Copyright © 2017 by The American Association of Immunologists, Inc.)- Published
- 2017
- Full Text
- View/download PDF